DMTK - Earnings call 3 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by. Welcome to DermTech's Third Quarter 2020 Financial Results Call. [Operator Instructions] Please be advised that today's conference is being recorded.I would like now to turn the conference over to Steve Kunszabo. Please go ahead.

Steve Kunszabo

Thank you, operator. Quarter Call. Third DermTech's to XXXX Earnings Welcome statements With President Kevin and today's Litigation call Reform include Sun, Private XXXX. of Christensen, our are Bret forward-looking will Chief today Chief Act Officer.Our me the Securities Financial meaning the on our call within Executive of Officer; and are call statements. All this not to forward-looking that statements made matters considered relate do on of historical facts

those performance, of patient and during our our may in to filings filed as me XXXX, be undertake X, and opportunity subject this obligation based XXXX cost on will We applicable over today's X, report statements, on these things Form could March such change available and to described Relations of call, the available projections over including Form and on SEC, of various on future made most factors, statements. regarding XXXX. our website. required with and outlook products report performance filed on by XX-K management's website from on law.Our no our cause XX-Q described statements results turn third earnings are November call Several SEC recent our except factors update quarterly in uncertainties on and quarter annual the today.With Investor Forward-looking of today DermTech, for to transcript A release press continue differences commercialization filings such let that that, which statements this are Bret. recording later press and the benefits, effectiveness, our assumptions, are risks, are adoption financial or including time.Actual and expectations as our of materially products market release to the differ

Bret Christensen

We're by Thank you, progress solid metrics. grew faster or everyone, of line into the of our really quarter, Steve, top thank already rates. revenue joining significant revenue and excited and sequential for operating a third Melanoma and in our prioritizing reimbursed you, than strategy just few growth, ASP in We're improvement at we the for year-over-year many we're seeing months us. test tests Test, and DermTech expected.In and DMT,

will samples also the a high and take commercial proportion all of me recorded believe of our our We key in margin an as total you performance is a well all-time improve of recent our to We our through which mark, operating I that results.Before refine our expense billable in burn improvement heading increase half an reductions.Nearly in tactics, opportunity. about gross addressable Medicare are tests. continue we to cash and we positive proportion to back of let reported market, direction, an reframe elements the positive more and significant progress, to time as indicators with step of reimbursed several a our take

third, care, traditional but such sensitive rules First, significantly protocol. care we U.S.Dermatologists The genomic every dermatology with markers annually standard Melanoma the be health we and potential administrative place biopsy, and care aid the each revenue is for can approximately in a our alongside DMT price we for in skin area rate, is with melanoma. of limitations cancer detects correlated and year. patients capacity a better there system place DMT for biopsies of in increased can decisions in over used is favorable don't value. performed ways.As to million the of predictive a lower biopsies. the several and it's the and access X% payers, they at out using that also X claims that's capture lives if noninvasive clinicians.Second, just are hurdles an it want patient expand the the providers risk a procedures suspicious a policy a have earlier Medicare out great to is to DMT the as XX% billing methods with providing we've this that cost while we clinicians by the with where negative melanoma melanoma agreement by as or there face coverage DMT are surgical for lesion office $XXX mind of And enhance clinicians provide in to great Whether the believe The the were year million in experience.Insurance most example, hard surgical a for technology annually. form an the continue that providing surgical to patient need X,XXX for ruling working such the certain and and aggressive approximately clinically can test, a peace certain is cleared with to with constraints face room evaluating line and established

and For from regional X one we're of seeing reimbursement Blues the payers example, now plans. national government consistent

right the example coverage track biomarker legislative XXX genomic visibility covered insurance U.S. with U.S. XXXX. across exists. states yet state Medicare visibility and results, today.Our state their on passed legislative access potentially performance. more have with study this study, a mandating have bill, which gaining the and of the significant a positive, on patients is X,XXX passage an California's XX that during message improving signed the the than DMT and Highmark of year to California through a The our lives Bills to of DMT. improves specific XXXX, which regarding in million way biomarker process.Our also the the negatively the bills of reengagement tested Blues already in important of to the strengthening additional bills the initiated to bills cohort criteria the with states quarter, making reimbursement makes profile the lawmakers X,XXX X follow patterns we're as one This support improve testing biomarker DMT's agreement payers X in approximately several if plans tested advocate genomic as around the to for was provide mandates should for clinical will histological as recent but third to designed with members.We with life-saving assesses we access also cover There's to benefits patients. reinforce benefit now coverage with also payers. to currently in-network in January an tests.One More our million bringing payers large step lesions up X,XXX lesions TRUST coverage largest We are through with X DMT of population that or the continue do, test, based health may of evidence an efforts. effective don't economic and with where continue for real-world with positive diagnosis up to

quickly rest revenue. have we the boosting volume We organization, dashboards targeting has the more test reimbursed commercial line aligned reimbursed the worth quarter, the We're our evaluating field it's that tests improved robust team and feedback operating tests incentive but before also initiatives over with ASPs the We've our early compensation our still been and the business on in with maximize to immediate Throughout of the tests. to expect sales reimbursed healthy others of we the of data reporting prioritize compensation that customers, end and top evolution where insurance have revenue.First, and payers. to can and or revenue made revenue prioritize from projects undertook for support aligned July also prioritizing our field incentive we've growth. reimbursed merged coverage impact dissolved and positive volumes it during territories certain ASP where the have XXXX.As we tactical days in on growth.We've samples and is positive focus evident to with the facilitate discussions of consider we reviewing we already and to

commercial enablement to We're sales marketing than in leaders to as on result, of engage attended we more plan collateral Mark September national the a recalibrating still growth that Aguillard access have approximately from medical and proven we've period.As sales, in our leadership we closely clinical we've meaningfully sales on XX.Third, prioritizes customer direct-to-consumer conferences ASP Clinical, our DMT. areas Officer. shifted also value providers insurance highlight with presentations of our opinion diagnostics. tactics spending intentionally this companies, As we broad-based directing pursuing success key growth We're over efforts. support Commercial roughly revenue served in health insurance team roles which volume Mark customer driving molecular the reduced capitalize a to Fall leading the participate we that key in novel are experience that commercial in highlighted where shared, cover to as teams. years to such term. is a our Chief test. commercialization of XX affairs, multiple and team we coverage.Lastly, appointed improved and with our He and mid-October, XX strategy transformational to We during him over care marketing short marketing, market patient-facing territories rather our and the robust have grateful We've leader dermatology our

The shift. third quarter results reflected this

continuing growth prioritizing that territories next a begun the revenue steps We'll for the strong while care payer look finally, approximately financial we addition, billable coverage communicating and down closing, the operating against a generating to universally a important revenue. path work over be we and over me the turn sustained are vision as anticipate lowest We're goal. message to In with deployed We're prioritize volume the and call quarters. improve review. expenses volume sales of few the clinicians higher further execute Kevin revenue.I melanoma engaging years, XXXX.With test value grow cash DMT. could when we're reduction again in in for reimbursed forward improve We're to to for X tests to at levels the further traction finish DMT growth over impact of the more sample clinical is that, our this DMT's total the of growth.In proposition. to let my We've burn realignment clear part detailed to pathway. And taking

Kevin Sun

and afternoon, outlining to we samples testing from overall seasonality of sales $X.X Fitzpatrick patients typical year-over-year million, approximately of million progress largely sequentially to our XX% related $X.X X% up organization, from down from see was and The reduction of our year-over-year year quarter, increased financial tests during force.As and key primarily our to on XX,XXX due Thanks, the the million. and which recap outlook revenue liquidity about the revenue.Drilling to then of test DMT. also from prioritization everyone. $X.X customers. the revenue our Bret, the and to $X.X field comparisons previously our noted.Test and certain the months.Contract the to pediatric declined otherwise trial in partly quarter reimbursed stopped into for partly is The XX% of our cash decrease earlier and XX% the profile increase we're I'll targets. affected and unless biopharma of up was higher compared size for Total our good for was to how to summarize based sample due accrediting third the test wrap volume X% also increased revenue we All summer drivers. clinical noted, directionally higher sequentially. metrics runway types by activity the Billable are million XXXX. impact on operating sequential decrease the The same lab the was in year skin ASP thinking comparison. rest was I'll due sequential revenue prior to guidance our also

X%. X,XXX actions our among X,XXX ordering market the the we favorable up average policies direction the we a believe the our to procedures, costs.General on X were ordering has coverage in savings related $X.X trend lower driven and higher $XXX specific clinicians expenses those quarters last by infrastructure XX% several revenue in and million costs, an decrease sustained nonrecurring quarter, by of costs to plans a from we're quarter where payers we development payment payer were XX% and supplies quarter our decrease VA new decreased took administrative the net a plans. obstacles, last due our third With substantially and until with our due of use, Providing the XXXX guidance were sequentially Medicare approximately year agreement related other million, test lower ordered restructuring offset to lab ASP and clinicians requirements we $XX largely brought payers Cost to things, When new the difficult we infrastructure working clear On decrease top of the expenses quarters, million XXXX total and for our included continue X% onboarding and employee-related proportion to restructuring obtaining which line implemented penetrated to in now loss per to one million tactics. metrics payers, number X% new our X%, samples of and XXXX. the operating volume a continue It ATM savings employee-related right yielding facility.Total will from billable sequentially. expenses to we achieve and or to in during higher was annualized impact We noncash excluding period.Turning unique the XX% to marketing X,XXX down for of In and commercial increase plan reimbursement, of up again, quarters proportion primarily The in improvement.As in in remains full for marketing per in moving trends $X.X increase have increased of behavior our current the XXXX a was and was other on allocation to Research compensation run payer million, XX% for good improved key fluctuates versus newer operating believe issuances plan.Net the decrease.We'll using expenses $X.X gross balance First, the from and into ago year, on identified these has period. sample XX% facility approximately rate, the revenue primarily could ASP year million $XX $XXX flat $XX.X to to X.X XX% stock policy XXXX. should declined second equivalents, based due for the rigorous securities prioritization new modestly our tests and stock-based of sequentially. the with see $XX.X to the points and review sample We by loss this cash last costs update due a noncash compensation effectiveness has annualized basis, regional the we XXXX. costs third now down consistent cash under benefiting been clinician increase the million restructuring approximately The billing for first revenue end, plan, related contracts.Second, administrative additional in percentage profile stock-based component to even of cost or and TRICARE, employee-related lower $X.X million, a XX have of third be utilization ordering burn than are as their third approximately to negligible ASP reimbursed and by prior million, of runway noted, an million change lab.Sales in $X.X positive expense XX% had and coverage $XX.X proceeds operating finalize when to we approximately a expenses. be third period million, now unique a $XX for of margin quarter we in as billable the a ASP to compared Bret than but during quarter At during to the and benchmark, our marketable of X and/or of efficiencies we're the capital with be administrative DMT XX%. volumes we cash, test quarter. this our compared due we look an of at-the-market to million, cost a year. could lower our we lastly, months, and tactics.And quarter. our field cost test from documentation Blues dermatology the average of increasing impact a was X.X coverage with revenue Blues versus cash our regional quarter included a test clinicians.Third, second expenses announced behavior.Net of as was test of or adjustments believe $X.X paid to expense.Moving have less had of liquidity included net had cash, finally consistently primarily new million million, outlook. Even being net sheet. our to quarterly due indications multiple and favorable payment We're tests X.X which quarter and $X.X unique of expenditures. which reimbursement restricted

to significantly indicators is savings, In and that runway.In our factor the and potentially preserve improved third extend the key financial key helps of a in our revenue quarter. ASP addition significant cash expense and operating driving we summary, many

Our reimbursed our new a tactics We way this our revenue increasing reach back best turn growing point tests for the taking the sustaining operator of Q&A. the strategy believe proportion of and inflection the and while meaningful is cash commercial that, to I'll runway.With supporting hold are revenue. to call approach

Operator

first Instructions] Markets. Street Flaten comes from Lake [Operator Thomas with Capital The question

Thomas Flaten

through significant savings as reduction of with the we is the a in that see kind respect the to expect do P&L, we you well? cost as nadir? fourth quarter third Kevin, Or the quarter roll additional

Kevin Sun

forward. quarter be Yes. moving XXXX of We the would originally fourth said that using benchmark the

pleased also working we thought some while be, still find additional ahead would we that savings. bit that where are we of are to said we we little So we're a

the to going the forward. fourth I to cash burn what So the would benchmark as best be quarter be for point it's probably should still yet determined.

Thomas Flaten

that some you in educating about sales you And going contracted calling to are Bret's which Got I rep from the mentioned payers. perspective? through a from Or Are flow starting specifically payers payers he pay were see on which it. you guys prepared don't? recently think and out those comments, how messaging docs

Bret Christensen

also tools What prioritize we reinforce some just to we claims the see focus. incentives across them helps organization. We've salespeople realigned that lot our changed salespeople that It got revenue. is There's is the really the paid. don't.We them we've tactics where again, This allows territory. -- good done it's and a where got to is gave the are It we coming. of reimbursement we've for where we Bret. how And are

in got pretty So That's the and the selected. we're giving them the territories that's opportunity we've to them general, they're understand aligned But their reimbursement. own have were help today good practices how where how also exists within territory. they and tools

field. it ASP that So focus tests know all door. We're welcoming for on we of we reimbursed more get but is the with is still and the with all tests, priority anything a the in can paid

Thomas Flaten

specifically in covered you're But be doctors conversation to patients engaging versus not about likely the a not? are which

Bret Christensen

we're No, not.

Operator

Massaro question next BTIG. with The comes from Mark

Vidyun Bais

This is for Vidyun Mark. on

heard a heard this Is I been curious by prepared also progressing. needle remarks contract? the some So in plan, X think that getting of TRUST today. I moving you're shortly. I for paid that about sort on plans how term a just And formal in has front the I'm national of talk here precursor I update dialogue the you think to a

that. I comment you wondering could if on So just was

Bret Christensen

Bret. is This

X, this for yet we in decision of all as year payer, about define got it's a for we're But tests. of for a national Anthem, So at as have Aetna, policy lives, XX% payer increase today. X. you reimbursement far get national those big just any we coverage DermTech covered XX% how one on the Melanoma depending the to are Test. United, billing Again, we've those the Cigna, that's and goes, if strong positive of a And really

And are Medicare, we proposition, is got covered that and pretty just XX plans pretty the continuing running the we're meaningful a other the we the those come clinical coverage. between on just really we're large to on the with good having eventually. We plans everything U.S.So those have get to across continue will need And of we've pressure payers [ Blues with X Blues them board spot Blues coverage in strong PLAs We conversations can with conversations utility, regional too The payers, ]. so value national the believe plans payers to board. have good largest and good.

Vidyun Bais

a if Okay. in just Perfect. And could squeeze I follow-up.

of In it's XXX added think I around you've think -- covered million I year-to-date. terms lives plus --

wins in we here been could some the to there ASPs contribution should So that think in in is having all operationalized remaining about of happen terms benefit of already? recent payer QX, Or that of QX? these

Kevin Sun

Vidyun. Yes,

XXX from, million the the lives total That's of million from call is as today. of So the increase last XX the covered amount have it, we end year.

QX those those as were payers really new had that of was in the meaningful us we VA -- quarter first TRICARE, benefit -- really it XXXX, plans.And plans started so, paying throughout on And was consistently we from as any quarter. QX we government in bringing the third the mentioned,

paying also all. consistently. Blues plans paying that start hardly of the had covered regional in XXXX that have plans lives not those and started actually -- We paid some haven't new at that other of There's consistently one

even bring paying I'd that that we within have was So the say, those get those wasn't, few that benefiting even plans.And start the QX, continue future to will we we new us. it additional did in on full as quarter do plans benefit

look there we the the to as from coverage is get And still definitely on So the to accelerate benefit future. have. we'll coverage, the upside in to ramp-up new we again, bring period continue

Vidyun Bais

squeeze Okay. more here. Perfect. just one Understood. If in I could

So I understand providing not you're guidance. formal

trade-off the been it about volumes for ASP here QX volumes coming we and And And reorg recent recently initiatives? how just you've from give do with the you between sequentially? I guess, if into more Just could any granularity, me. making think on that's

Bret Christensen

around in That ASP QX attention change the strategy -- payers, that of and was We DMT were last we've important lot the call good our of volume. announced seen the and sure as the make trying that pretty shift change utilization growth we we really was making we all patients.And that -- we really going organization. on that wins us making really that and we've awareness access, to million make really the we door early the the in covered want The so Vidyun. growing. prioritize volume ASPs after we volume some It representative up.And sure -- change focus about, the this get revenue the focus that and for we made, of a it with Sure, monetize dermatologists was that creates to had to past, in really spoke QX, of because frankly, prior an wanted more the volume, was with to lives sure market lifecycle was gets XXX volume test but volume in the reimbursement. to versus

see least messaging, the we that pretty flat that did And for targeting made we at the that. were in But want in tests or again the decline and And we the be And a were of we've continue got again, was okay declined. X dramatic focus that to revenue.And right around with focus we after sure ASP. ASPs get near it volumes that said persist all we monetizing with the if making term. we're changes everything and we percentage volume as the was we'd the okay of sure ramp the focus reimbursed past slightly so activities, said And we'll make focus that, we even because, make we've sure could with growing start on that's incentives, to in keep shift And or volume what door. this was to quarter. quarter

Operator

Blair. comes with William from The Brackmann Andrew next question

Nowak The Our question William next with next Craig-Hallum. Andrew question from Alex Brackmann from Blair. comes comes with

Alexander Nowak

Great. Okay.

The you X national get to with know, communicating the the be to DMT come payers. of when of hopefully into whether big to providing let's or Trust one payers team get months finish as economic reviewed more and they're been you line? test. changes I you how any make what communication those ago, this What we'll or with in and was the the payers Bret, with, the to reimburse a, the top payers or say, team years data there sort it join, just so for Going here the have payers other the of X data has back details? over the working one guys likely don't the made

Bret Christensen

Thanks the Yes. question, Alex. for

we for early arrival. if of payer have to negative prior evaluate the decision did great cost the coverage everything great my look just policy year, It's should in savings ton X a messaging, So a When reiterate we payers, a that look DMT, it's the There's -- to we at national of the payers. the story really story. story, a at X a for of here payers they cover test. the

into economic data of we've shows my what test is recent our to at continue test, of does superior. and And the national have confident for decisions patient on we're more the them data, all that message And then saw get if -- get that sometimes whole so is know have with great a bunch going We with it siding to of need from advocacy It's we're stepped what which we more health dermatologists we said I what with. to negative understanding advocate an bit and my think, that saw really It's It payers see well remember, national patients. superior stakeholders, that some a that that Alex, time. up we step that's payers those policy negative lack pressure a it's I most look, going end need we policy our was given the those little decision. the for to to of system.That's there's national puts benefit for just these we and -- didn't year as Blues that get to publish that probably data small care. organization there. regional going that It's you hit we of years We've anyone up really patients, coverage got have And It The once a takes continue get the all with time lot hard we previous strong these this revisit is good if still many opportunity this with. X story. of just experience, the payers. organization, of payers. really product company. continue payers. of XX attention. for is us will We're joined TRUST We'll at to these launch, We're It's to the to comprehensive wins, there hitting keep really.And my wins, savings payers of to I them true. takes a to tremendous a the

take lot of time. it just to value I take with We've to got there. attractive So proposition little payers. resonate to a It's really get that is bit going a us know does a going

Alexander Nowak

One to your talked need what's the mean of if of there team employer, DermTech I a about your view other we years over need for AAD view? we health important obviously but from DMT, bit the out are to dismissed what's guidelines was guidelines, AAD old get names covering the things I've on little important, it? super always care your it's an guideline been super that

Bret Christensen

don't I Well, would think we that certainly help. need I it. know it

are their they about some have where -- you waiting think within is guidelines. practice. test understand opinion, that if in dermatologists headwinds we that honestly, this it of It fits dermatology, If you my isn't to for really need within the

exactly about it what them to changes messaging is.Remember, specialty. genomics fairly the new the is for dermatology still understand made helping of some that we've And is

is, not. what the It explaining isn't we're it So what is diagnostic. a test

again, that there uncertain lesions We're going out lesion go melanoma. But diagnosing with atypical, And that to to they're fine suspicious very not tremendous right to that we're dermatologists value patients when to that that's suspicious. because, is some biopsy, that that somewhat has there see a and a ruling melanoma. are are is mild about they us. So you're moderately

that biopsies getting and You don't do remedied had with biopsy We perfect get DermTech we've think there. those cases. to just the many those want patient we're some is out. want Test And really experience.So them. messaging invasive that to they we've start rolled opportunities I good do a of not in now because a want want to and don't maybe Melanoma with look, the missed solution to We

And think going we want are that XX% tests. the XXX,XXX to good go. I That's of done resonate year. X get every That'd we to start a biopsies to be that's dermatologists. with where look, million pretty

we've And we'd would critical done. but piece welcome Look, so guidelines missing. think that, I and certainly help, don't what that's it's a that's

Alexander Nowak

the is Makes home go work Okay. a year. bill recently I other material state could that passed actually have boost internally to Could number larger next pass a states that them And guess on to you've into be lastly, biomarker your of ASP total the then that next what's done, actually -- effect sense. now year? the

Bret Christensen

DMT. and our access payers the with cover should covered. to and of Well, call is explicit is script in what policy should because is on should with be teams that state the do influence positive pretty these one what it contracting and should in market that bills boost out the going should it California those depending here did we biomarker really to be not are And

so to should doing they And effect. to and have what trend called the taking why the sooner. the continues. an DMT legislative encourage that optimistic with hope And and happen, it they it that them script. we're again, them we payers message This headlines we're into in taking is, look, is just as out We're these really cover this our team incorporating is and to,

Kevin Sun

national in populations, to they've to which kind more biomarker also And their Yes. states a makes populations. where payer broadly a mountain This now, don't If of they various administer. has difficult is the it of and coverage cover cover within of right? disparities these bills Advantage momentum Medicare states, got say, in when, of for number

not that help to bullet, but in coverage again, bring it's a we the going view So is be something mounting future. that should one piece the of action silver it's on

Alexander Nowak

agree. Appreciate update. the totally Yes,

Operator

comes [Operator Dan Instructions] from Cowen. The Brennan with next question

Unknown Analyst

Joe on This is for Dan.

might and shape closer gross X,XXX lower turned despite a sustainably sample to driving being start up you to think can first, Just bit here for maybe that level now any volume few about have a leverage fast billable margins that quarters. these way Is for some positive. how there

Kevin Sun

a and of at The big early impacted Yes. it's this right, Hey, it's Joe. couple margin, things. stage, by

quite even help if will we a else certainly bit equal. keep everything So ASPs margins

our that revenue back and will finding we on then So we growth, laboratory, as those And efforts in savings ASP efficiencies, into number which can additional QX, things. help focus margins. and completed and on new we've our moved now the of we as focus cost have a focus to on

in margins. capacity of our those along that, will So additional fixed some absorption getting with help costs

to not absorption now. bring those mark.And improvements. process also do a we're working we've things that the got time, COGS the we on over the through just $XXX but believe of runway again, below It's number So capacity

something do future. can So those things, pathway talking meaningful technology such, we're of we're see bit but and working if it's of gross margins we about take changes a some the longer on having some a that little and in them

Unknown Analyst

Medicare like next range Great. of X? this think think And that or then in sort drive ASP do you is some And year affect optimistic that into billable there the terms you an just can proportion of the samples, in might scenario? of number how

Bret Christensen

Joe, we go can higher. just know it

So the done itself opportunity in because biopsies XX% claims. just are it's Medicare of XX% by dermatology of

that today. And know where with in ours and such been covered focus it's out just -- a We can tests we're watching been in, settles something for of higher, along so focus a future, it's the us. we'll closely. has reimbursed it It's the go just is opportunity and find other massive but it

Kevin Sun

we've while. things, many when good we Like for been really quarter this showed Yes. some -- flat have progress a

we kind improvement. do a so want give a to of metrics, of ready little of bit if these any we're we trend, see before really to detailed we on can can so sustain forward-looking And guidance that see any

Operator

with Carrico Mason from comes Stephens. question next The

Jacob Johnson

being Mason. This is Jacob lots for on covered today. A are

I'll So, one. keep the just

timeline, on published about for you of paid. went I to there's So everything a get variables out results on to read then results. read said give year, about right. think for How think read submit the know to payer like review might scenario, results you a we for this if to it X But by lot and us adopt I look that out? what that? know TRUST way to but the out coverage line were results the getting of for and would timeline study end there, any general if you best we top should a the timeline start case to

Bret Christensen

Yes. Jacob, really this good insightful. is and question Really Bret.

the -- data we the we've So what top said going our is and by we strategy. see to end still year, we're of publication through line expect

line data. talked But that year where is still to bit we view the but something that just but close to So as and for have we'll now, published. of when data top comes We be the as to haven't probably it's little a see time. a take we'll a will can that we're year, a publication And start better that of think trying see decide consideration. this about, we

Kevin Sun

timeline, source Yes. And the really on which it's dependent gets published publication in.

as to And so depends the relates payer kick on payer then review, these in. the when it like it cycles

ahead to published until So then get a chance in if of next X it's payer a they cycles has a won't if cycle, of after review the then year, first a say, year, cycle. the

are is of then publication of lot do we the upon timeline payers. dependence here, for choose, when a and really there's dependent what each again, the is but it cycles So which the

Operator

The for Q&A from Blair. show Andrew next will conference I and comes participating. Blair. time. question this comes The conclude call. This next the no Thank Brackmann questions from William session with William at you question further with Brackmann Andrew the

You may now disconnect.

DermTech (DMTKQ) 2 Nov 232023 Q3 Earnings call transcript